News + Font Resize -

AstraZeneca to buy Takeda’s respiratory business for $575 mn
United Kingdom | Thursday, December 17, 2015, 09:00 Hrs  [IST]

AstraZeneca has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited (Takeda). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015. Full acquisition of the global rights will support AstraZeneca’s respiratory franchise and complement the company’s portfolio of treatments for severe COPD. Recent data reinforce the benefit Daxas brings to patients in reducing exacerbations as an add-on to dual and free-triple inhaled combination therapies. The agreement will also provide AstraZeneca with access to other marketed respiratory medicines and early pipeline products.

Under the terms of the agreement, AstraZeneca will make a payment of $575 million. Approximately 200 staff will transfer to AstraZeneca upon completion.

Luke Miels, executive vice president, global portfolio and product strategy at AstraZeneca, said, "The agreement with Takeda complements our respiratory business, one of our three main therapy areas, supports our return to growth and will be immediately accretive to earnings from 2016. Daxas in particular adds to our portfolio of treatments for patients with severe COPD.”

Annual global sales of the three core medicines acquired, excluding any AstraZeneca sales of Daliresp in the US3, were $198 million for the period ending in March 2015. The transaction will be accounted for as a business combination and is expected to close during the first quarter of 2016, subject to customary closing conditions. It is expected to be immediately accretive to earnings from 2016. The acquisition of global rights to Daliresp will also negate the company’s existing royalty payments for the medicine in the US.

Daliresp (roflumilast) is available in the US as a treatment indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Daliresp is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

Daxas (roflumilast) is available in Europe as a treatment indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50 per cent predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

Daliresp/Daxas has a unique position in severe COPD as the only PDE4 inhibitor that reduces the rate of COPD exacerbations in a subset of patients who still suffer from exacerbations despite maximum bronchodilation up to 45.5 per cent, depending on background therapy and previous exacerbation pattern. Daliresp/Daxas has also been shown to reduce hospitalisations due to severe exacerbations.

Post Your Comment

 

Enquiry Form